Double IOP system effective in patients with macular degeneration

Article

The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.

The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.

Luis Amselem from the Hospital General Universitario, Valencia, Spain and colleagues evaluated the efficacy of a standard double IOP system in patients with low vision and central scotoma due to macular degeneration. The interventional, prospective, non-comparative case series included 13 consecutive surgical procedures in 10 patients.

At 12-months follow-up the difference between pre- and postoperative BCVA, refraction, position of IOLs, endothelial cell density and occurrences of postoperative complications were evaluated.

At 12-months, mean BCVA was 0.68 logMAR compared with 1.37 logMAR preoperatively. Mean best corrected clinical gain was 44%.

No statistically significant difference between the clinically evaluated and theoretically calculated residual refractions was recorded and there were no intraoperative or postoperative complications.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.